Bertilimumab

{{Short description|Chemical compound}}

{{Drugbox

| Verifiedfields = changed

| verifiedrevid = 459958463

| type = mab

| mab_type = mab

| source = u

| target = CCL11 (eotaxin-1)

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 375348-49-5

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 60879E4NED

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| chemical_formula =

| molecular_weight =

}}

Bertilimumab is a human monoclonal antibody that binds to eotaxin-1, an important regulator of overall eosinophil function.

It was discovered by Cambridge Antibody Technology using their phage display technology.{{cite journal | vauthors = Main S, Handy R, Wilton J, Smith S, Williams L, Fou LD, Andrews J, Conroy LA, May R, Anderson I, Vaughan TJ | display-authors = 6 | title = A potent human anti-eotaxin1 antibody, CAT-213: isolation by phage display and in vitro and in vivo efficacy | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 319 | issue = 3 | pages = 1395–404 | date = December 2006 | pmid = 16973884 | doi = 10.1124/jpet.106.110734 | s2cid = 20865759 }} Named CAT-213 during early discovery and development by CAT, it was to be used to treat severe allergic disorders.{{cite journal | vauthors = Ding C, Li J, Zhang X | title = Bertilimumab Cambridge Antibody Technology Group | journal = Current Opinion in Investigational Drugs | volume = 5 | issue = 11 | pages = 1213–8 | date = November 2004 | pmid = 15573873 }}

In January 2007, CAT licensed the drug for treatment of allergy disorders to iCo Therapeutics Inc.{{cite web |url=http://www.icotherapeutics.com/site/investor-relations/cambridge_antibody_tech_licenses_monoclonal_antibody_treatment_allergy/ |title= Cambridge Antibody Tech. licenses monoclonal antibody for treatment of allergy disorders to iCo | publisher = iCo Therapeutics |access-date=2009-08-01 |url-status=dead |archive-url= https://web.archive.org/web/20090501222201/http://www.icotherapeutics.com/site/investor-relations/cambridge_antibody_tech_licenses_monoclonal_antibody_treatment_allergy/ |archive-date=2009-05-01 }} iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications - a so-called 'search and development company'.{{cite web |url=http://www.icotherapeutics.com/site/corporate_overview/overview/ |title=iCo Therapeutics | publisher = iCo Therapeutics |access-date=2009-08-01 |url-status=dead |archive-url=https://web.archive.org/web/20090728050145/http://www.icotherapeutics.com/site/corporate_overview/overview/ |archive-date=2009-07-28 }}

iCo Therapeutics Inc. renamed the drug from CAT-213 to iCo-008 and, at that stage, planned to initiate a Phase II clinical trial in patients with vernal keratoconjunctivitis.{{cite web |url=http://www.icotherapeutics.com/site/pipeline/ico008/ |title= iCo008 | publisher = iCo Therapeutics |access-date=2009-08-01 |url-status=dead |archive-url=https://web.archive.org/web/20090728131313/http://www.icotherapeutics.com/site/pipeline/ico008/ |archive-date=2009-07-28 }}

In March 2008, iCo announced iCo-008 had been in 126 patients in Phase I and II clinical trials. The drug substance had been manufactured by Lonza, in its cGMP facilities in Slough, UK. Subsequently, iCo moved the drug substance to a fill-finish site for the final stage of manufacturing. iCo reported that the iCo-008 drug product was within specifications and contained a high antibody yield.{{cite web |url=http://www.icotherapeutics.com/site/investor-relations/ico_therapeutics_provides_ico_008_phase_ii_clinical_update/ |title=iCo Therapeutics Provides iCo-008 Phase II Clinical Update | publisher = iCo Therapeutics |access-date=2009-08-01 |url-status=dead |archive-url=https://web.archive.org/web/20090501230056/http://www.icotherapeutics.com/site/investor-relations/ico_therapeutics_provides_ico_008_phase_ii_clinical_update/ |archive-date=2009-05-01 }}